The few pharmacoeconomic studies showed that rapid-acting insulin analogues in type 2 diabetes could be associated with a favorable balance of costs and effects due to the small effects on the hypoglycemic risk and the possible increase of quality of life. The gene discussed is INS; the disease is type 2 diabetes mellitus.